Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target...
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global...
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years...
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable...
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia...
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts...
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART®...
February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지